Long-term follow-up after conversion from tacrolimus to cyclosporin in renal transplant patients with new-onset diabetes mellitus after transplantation.

INTRODUCTION: The relationship between anticalcineurin (CNI) drugs and the development new-onset diabetes mellitus after kidney transplantation (NODAT) is well established. Among these agents cyclosporine shows lesser diabetogenicity than tacrolimus. It has been described that conversion from tacrolimus to cyclosporine improves glycemic control; however, there are no studies showing whether this reduced risk is maintained upon long-term follow-up. OBJECTIVE: To evaluate whether CNI drugs conversion from tacrolimus to cyclosporine helps to maintain better glycemic control. MATERIALS AND METHODS: We retrospectively evaluated the evolution of glucose metabolism at 5 years after conversion from tacrolimus to cyclosporine in eight patients (six men) with NODAT. Mean age was 42.8 ± 15 years, and time after transplantation to conversion 128 ± 40 months. We analyzed fasting serum glucose, lipid metabolism, renal function, and cyclosporine levels at 0, 6, 12, 24, 36, 48, and 60 months after conversion. RESULTS: At 6 months after conversion, improved glucose metabolism was observed (268 ± 161 versus 121 ± 31 mg/dL; P < .01) although it was minimal in one case with persistent high blood glycemic levels. Only two patients maintained a normal glucose at the end of follow-up. Five subjects showed increased glycemia at 12 to 24 months after conversion requiring antidiabetic therapy: three patients, insulin and two oral antidiabetic agents. Two patients lost their allografts due to chronic rejection at 32 and 50 months respectively. Among the other six patients, renal function remained stable (1.9 ± 0.6 versus 2.11 ± 0.97 mg/dL; P = NS). There was no significant differences among the other variables. Cyclosporine levels remained stable during the follow-up. CONCLUSION: Conversion of renal transplant patients with NODAT from tacrolimus to cyclosporine improves glucose metabolism in the short term but glycemia increases thereafter.

Effect of CYP3A51/3 polymorphism on blood pressure in renal transplant recipients.

BACKGROUND: The cytochrome P450 3A5 (CYP3A5) enzyme has been implicated to determine blood pressure (BP) in humans. Different results have been reported concerning CYP3A5 gene polymorphisms and posttransplantation hypertension in kidney recipients. Our objective was to investigate whether CYP3A5 1/3 polymorphism was associated with ambulatory BP among a population of renal transplant recipients receiving the calcineurin inhibitor tacrolimus for immunosuppression. METHODS: Sixty primary kidney transplant recipients undergoing treatment with tacrolimus were genotyped for the CYP3A5 1/3 polymorphism. We analysed the association of the CYP3A5 alleles with ambulatory systolic and diastolic BP measured at 6 and 24 months posttransplantation. RESULTS: We observed that 23.3% of the patients were CYP3A5 1 carriers and 76.7% were homozygous for CYP3A5 3. CYP3A5 1 carriers showed higher adjusted systolic BP and diastolic BP at 6 and 24 months posttransplantation, and they were prescribed more antihypertensive drugs compared with non CYP3A5 1 carrier patients, albeit not significant. No significant differences were found comparing the distribution of the hypertension classes. CONCLUSION: We did not observe a significant association of CYP3A5 1/3 polymorphism with posttransplantation hypertension, although there were some differences in BP associated with the presence of the CYP3A5 1 allele.

Medida del grosor foveolar mediante tomografía de coherencia óptica en pacientes adultos con nefropatía diabética en hemodiálisis / Measurement of foveal thickness by optical coherence tomography in adult haemodialysis patients with diabetic nephropathy

Antecedentes: Diversos estudios han demostrado la eficacia de la hemodiálisis (HD) sobre el edema macular de los pacientes diabéticos. Objetivo: Estudiar los efectos de una sesión de HD sobre el grosor foveolar, mediante tomografía de coherencia óptica (OCT), en pacientes adultos con diabetes mellitus tipo 2 con insuficiencia renal crónica (IRC)estadio 5 secundaria a nefropatía diabética en HD. Pacientes y métodos: Se estudiaron 25 ojos de 14 pacientes a los cuales se les realizó analítica y OCT pre-HD y post-HD. Resultados: Como grupo, el grosor foveolar no se modificaba tras una sesión de HD en los 25 ojos estudiados (245,28± 52,21 µ frente a 240,40 ± 40,25 µ) (p = 0,428) (2% de reducción) ni se correlacionaba con ninguno de los parámetros clínicos o analíticos analizados. Al comparar el subgrupo de 13 ojos en los que el grosor foveolar no se modificaba o disminuía respecto al subgrupo de 12 ojos en los que el grosor foveolar aumentaba se encontró que en el primer subgrupo la temperatura del baño era significativamente mayor (37,00 ± 0,00 frente a 36,29 ºC, p = 0,008) y la conductividad significativamente menor (14,00 ± 0,00 frente a 14,29 ± 0,10 mS/cm, p = 0,030). Conclusión: La HD podría modificar el grosor foveolar retiniano en función de la modificación de parámetros como la temperatura del baño yl a conductividad (AU)

Background: Several studies have demonstrated the efficacy of hemodialysis (HD) on macular edema in diabetic patients. Objective: To study the effects of a HD session on foveal thickness by optical coherence tomography (OCT) in adult patients with type 2 diabetes mellitus with chronic renal failure (CRF)secondary to stage 5 diabetic nephropathy in HD. Patients and methods: We studied 25 eyes of 14 patients who underwent analytical studies and pre-HD and post-HD OCT. Results: As a group, the foveal thickness did not change afterone session of HD in the 25 eyes studied (245.28 ± 52.21 Ì versus 240.40 ± 40.25 µ) (p = 0.428) (2% reduction) or correlated with any clinical or laboratory parameters analyzed. When comparing the subgroup of 13 eyes in which the foveal thickness did not change or decreased compared to the subgroup of 12 eyes in which the foveal thickness increased we found that in the first subgroup the bath temperature was significantly higher (37.00 ± 0.00 versus 36.29 °C, p = 0.008) and the conductivity was significantly lower (14.00 ± 0.00 versus 14.29± 0.10 mS/cm, p = 0.030). Conclusion: HD may modify the foveal retinal thickness as a function of changing parameters such as bath temperature and conductivity. Conclusion: HD may modify the foveal retinal thickness as a function of changing parameters such as bath temperature and conductivity (AU)

Measurement of foveal thickness by optical coherence tomography in adult haemodialysis patients with diabetic nephropathy.

BACKGROUND: Several studies have demonstrated the efficacy of hemodialysis (HD) on macular edema in diabetic patients. OBJECTIVE: To study the effects of a HD session on foveal thickness by optical coherence tomography (OCT) in adult patients with type 2 diabetes mellitus with chronic renal failure (CRF) secondary to stage 5 diabetic nephropathy in HD. PATIENTS AND METHODS: We studied 25 eyes of 14 patients who underwent analytical studies and pre-HD and post-HD OCT. RESULTS: As a group, the foveal thickness did not change after one session of HD in the 25 eyes studied (245.28 ± 52.21 µ versus 240.40 ± 40.25 µ) (p = 0.428) (2% reduction) or correlated with any clinical or laboratory parameters analyzed.When comparing the subgroup of 13 eyes in which the foveal thickness did not change or decreased compared to the subgroup of 12 eyes in which the foveal thickness increased we found that in the first subgroup the bath temperature was significantly higher (37.00 ± 0.00 versus 36.29 ° C, p = 0.008) and the conductivity was significantly lower (14.00 ± 0.00 versus 14.29 ± 0.10 mS / cm, p = 0.030). CONCLUSION: HD may modify the foveal retinal thickness as a function of changing parameters such as bath temperature and conductivity.

Niveles de 25 hidroxivitamina D y riesgo cardiovascular en una cohorte de pacientes con enfermedad renal crónica avanzada / 25 hydroxyvitamin D levels and cardiovascular risk in a cohort of patients with chronic kidney disease

Introducción: Los niveles bajos de 25 hidroxivitamina D han sido relacionados con un aumento de la morbimortalidad de origen cardiovascular en la población general y en pacientes con enfermedad renal crónica. Objetivo: Nuestro objetivo fue estudiar los niveles de 25 hidroxivitamina D en un grupo de pacientes con enfermedad renal crónica estadios 4 y 5 prediálisis, y relacionarlos con los antecedentes de enferme- dad cardiovascular y con factores conocidos de riesgo cardiovascular. Material y métodos: Se trata de un estudio observacional transversal de una cohorte de 171 pacientes seguidos en la consulta prediálisis de nuestro hospital, me- dia de edad 64,16 ± 13 años, el 59,6% hombres, el 64,3% diabéticos, el 47,3% obesos y el 46,8% con antecedentes de enfermedad cardiovascular. A todos los pacientes se les mi- dieron los niveles séricos de 25 hidroxivitamina D y de 1-25 dihidroxivitamina D, se recogieron datos clínicos y analíticos de función renal, anemia, perfil lipídico y metabolismo óseo-mineral; también se evaluó la presión arterial mediante registro ambulatorio de 24 horas (MAPA) y se realizó estudio ecocardiográfico. Resultados: La media de los niveles de 25 hidroxivitamina D fue de 22,1 ± 13 ng/ml, sólo un 18,7% de los pacientes presentaban niveles normales, un 58,5% presentaban niveles insuficientes o bajos y un 22,8% niveles deficientes o muy bajos. Las variables que se asociaron con los niveles bajos de vitamina D fueron la edad, la diabetes, el sexo femenino, la obesidad, el filtrado glomerular y el antecedente de enfermedad cardiovascular. Dentro de los parámetros asociados a la presión arterial, la presión del pulso fue la que más se relacionó con los niveles de vitamina D. No se encontró asociación entre los niveles de 25 hidroxivitamina D con otros parámetros del metabolismo óseo mineral ni con los valores ecográficos de hipertrofia ventricular izquierda. En el análisis multivariante las variables que más se asociaron al déficit de 25 hidroxivitamina D fueron el sexo femenino, el antecedente de enfermedad cardiovascular, el filtrado glomerular y la presión del pulso del MAPA. Conclusiones: Nuestro estudio confirma una alta prevalencia de insuficiencia y deficiencia de 25 hidroxivitamina D en la población con enfermedad renal crónica avanzada; este déficit se asocia con la presencia de factores de riesgo cardiovascular y con el antecedente de enfermedad cardiovascular. Sin embargo, no se encontró ninguna asociación con uno de los principales predictores de eventos cardiovasculares como es la hipertrofia ventricular izquierda (AU)

Background: Decreased 25 hydroxyvitamin D serum levels have been related to an increase in cardiovascular morbility and mortality in both general population and chronic kidney disease patients. The aim of this study was to evaluate the relationship between 25 hydroxy vitamin D serum level, cardiovascular risk factors and previouses tablished cardiovascular disease in a group of patients with advanced chronic kidney disease. Material and methods: We performed a cross-sectional observational study in a cohort of 171 stage 4 and 5 chronic kidney disease out patients seen in our predialysis clinic, mean age64.16 ± 13 years, 59.6% were men, 64.3% had diabetes,47.3% had obesity, 46.8% had previous cardiovascular disease. 25 hydroxy vitamin D and 1-25 dihydroxy vitamin D were measured, we also determine other routine biochemical parameters. All subjects underwent anechocardiogram and 24 hours ambulatory blood pressure monitoring was also performed. Results: Mean 25hydroxyvitamin D levels were 22.1 ± 13 ng/ml, only 18.7%of the patients had adecuate levels, levels were insufficient in 58.5% of the patients and deficient in 22.8% of them. Low 25 hydroxyvitamin D levels were significatively related with age, diabetes, female gender, obesity, MDRD glomerular filtration rate and previous cardiovascular disease. Pulse pressure was the Ambulatory Blood Pressure Monitoring parameter that was better correlated with 25 hydroxyvitamin D levels. We could not find any association between vitamin D levels and other bone and mineral metabolism parameters. No relationship was seen between low vitamin D levels and left ventricular hypertrophy. On multivariate analysis lower levels of 25 hydroxyvitamin D were independently associated with female gender, previous cardiovascular disease, MDRD4-GFR and higher pulse pressure. Conclusions: Our study confirm a high prevalence of 25 hydroxyvitamin D insufficiency and deficiency in advanced chronic kidney disease patiens, this was associated with the presence of cardiovascular risk markers and previous established cardiovascular disease. However we could not see any relationship with left ventricular hypertrophy which is an known predictor of future cardiovascular events in this population (AU)

¿Minimiza el carvedilol los requerimientos de fotocoagulación láser en la retinopatía diabética? / No disponible

No disponible

[25 hydroxyvitamin D levels and cardiovascular risk in a cohort of patients with advanced chronic kidney disease]. / Niveles de 25 hidroxivitamina D y riesgo cardiovascular en una cohorte de pacientes con enfermedad renal crónica avanzada.

BACKGROUND: Decreased 25 hydroxyvitamin D serum levels have been related to an increase in cardiovascular morbility and mortality in both general population and chronic kidney disease patients. The aim of this study was to evaluate the relationship between 25 hydroxyvitamin D serum level, cardiovascular risk factors and previous established cardiovascular disease in a group of patients with advanced chronic kidney disease. MATERIAL AND METHODS: We performed a cross-sectional observational study in a cohort of 171 stage 4 and 5 chronic kidney disease outpatients seen in our predialysis clinic, mean age 64.16 +/- 13 years, 59.6% were men, 64.3% had diabetes, 47.3% had obesity, 46.8% had previous cardiovascular disease. 25 hydroxyvitamin D and 1-25 dihydroxyvitamin D were measured, we also determined other routine biochemical parameters. All subjects underwent an echocardiogram and 24 hours ambulatory blood pressure monitoring was also performed. RESULTS: Mean 25 hydroxyvitamin D levels were 22.1 +/- 13 ng/mL, only 18.7% of the patients had adequate levels, levels were insufficient in 58.5% of the patients and deficient in 22.8% of them. Low 25 hydroxyvitamin D levels were significantly related with age, diabetes, female gender, obesity, MDRD glomerular filtration rate and previous cardiovascular disease. Pulse pressure was the Ambulatory Blood Pressure Monitoring parameter that was better correlated with 25 hydroxyvitamin D levels. We could not find any association between vitamin D levels and other bone and mineral metabolism parameters. No relationship was seen between low vitamin D levels and left ventricular hypertrophy. On multivariate analysis lower levels of 25 hydroxyvitamin D were independently associated with female gender, previous cardiovascular disease, MDRD4-GFR and higher pulse pressure. CONCLUSIONS: Our study confirm a high prevalence of 25 hydroxyvitamin D insufficiency and deficiency in advanced chronic kidney disease patients, this was associated with the presence of cardiovascular risk markers and previous established cardiovascular disease. However we could not see any relationship with left ventricular hypertrophy which is a known predictor of future cardiovascular events in this population.

Primoinfección por citomegalovirus como causa de desarrollo de crioaglutininas y crioglobulinas en una paciente sometida a trasplante renal / No disponible

No disponible